These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 12459377

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
    Taraboletti G, Micheletti G, Dossi R, Borsotti P, Martinelli M, Fiordaliso F, Ryan AJ, Giavazzi R.
    Clin Cancer Res; 2005 Apr 01; 11(7):2720-6. PubMed ID: 15814654
    [Abstract] [Full Text] [Related]

  • 11. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.
    Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S.
    Cancer Res; 2002 Jul 01; 62(13):3711-5. PubMed ID: 12097279
    [Abstract] [Full Text] [Related]

  • 12. Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.
    Kleespies A, Köhl G, Friedrich M, Ryan AJ, Barge A, Jauch KW, Bruns CJ.
    Neoplasia; 2005 Oct 01; 7(10):957-66. PubMed ID: 16242078
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.
    LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, DeLuca PA, Evelhoch JL, Boerner SA, Wheeler C.
    Invest New Drugs; 2008 Apr 01; 26(2):159-67. PubMed ID: 18219445
    [Abstract] [Full Text] [Related]

  • 18. Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.
    Bradley DP, Tessier JJ, Ashton SE, Waterton JC, Wilson Z, Worthington PL, Ryan AJ.
    Neoplasia; 2007 May 01; 9(5):382-91. PubMed ID: 17534443
    [Abstract] [Full Text] [Related]

  • 19. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
    Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S.
    Clin Cancer Res; 2004 Nov 15; 10(22):7671-6. PubMed ID: 15570000
    [Abstract] [Full Text] [Related]

  • 20. ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer.
    McCarty MF, Takeda A, Stoeltzing O, Liu W, Fan F, Reinmuth N, Akagi M, Bucana C, Mansfield PF, Ryan A, Ellis LM.
    Br J Cancer; 2004 Feb 09; 90(3):705-11. PubMed ID: 14760388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.